<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00936299</url>
  </required_header>
  <id_info>
    <org_study_id>08-0178</org_study_id>
    <secondary_id>R01DA022284</secondary_id>
    <nct_id>NCT00936299</nct_id>
  </id_info>
  <brief_title>Bupropion for ADHD in Adolescents With Substance Use Disorder</brief_title>
  <official_title>Bupropion for ADHD in Adolescents With Substance Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Attention deficit hyperactivity disorder (ADHD) is one of the most common co-occurring
      psychiatric disorders (30-50%) in adolescents with substance use disorders (SUD). Yet, little
      is known about the safety and efficacy of medications for ADHD in adolescents with SUD, since
      such youths have been excluded from most medication trials. Clinicians are therefore
      understandably reluctant to treat ADHD in substance abusing adolescents, often first
      referring such youths to substance treatment. Untreated ADHD is associated with poorer
      substance treatment outcomes. We address this research gap by proposing a randomized
      controlled trial of bupropion vs placebo in 130 adolescents (13-19 years) with Diagnostic and
      Statistical Manual (DSM IV) ADHD, nicotine dependence and cannabis use disorder (not
      excluding other SUD). Participants in both bupropion and placebo treatment groups will
      receive weekly individual manualized-standardized cognitive behavioral therapy (CBT)
      targeting SUD (at no cost to them) throughout the 16 weeks of the medication trial. Bupropion
      also is effective in treating nicotine dependence in adults; the majority of adolescents with
      marijuana and other drug abuse also smoke tobacco. More recent research in adults indicates
      that bupropion may reduce craving and use of other substances of abuse (e.g. methamphetamine,
      cocaine). It's possible impact on cannabis use disorder (the addiction for which most teens
      are referred to treatment) has not yet been evaluated. However since all drugs of abuse have
      a final common pathway leading to addiction via action in the so called brain reward system
      (ventral tegmental area (VTA), accumbens) -an important secondary aim is to evaluate
      bupropion's potential impact on craving and use of marijuana (MJ) in addition to its known
      similar action on nicotine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research has shown that bupropion is a safe and effective treatment for both ADHD and
      nicotine dependence in individuals without SUD, and newer research provides empirical support
      for its unique pharmacotherapeutic properties and potential for treating other addictive
      disorders (e.g., methamphetamine dependence, pathological gambling). No controlled studies
      have yet evaluated bupropion's safety and efficacy for ADHD and SUD (including nicotine and
      cannabis) in adolescents. The lack of research on the safety and efficacy of medications in
      adolescents with SUD and psychiatric comorbidities contributes to a serious lack of
      integrated treatment for commonly co-occurring mental health and substance problems in
      community-based adolescent drug treatment programs. This then contributes to poorer treatment
      outcomes and prognosis for the large number of comorbid youths with substance abuse and
      mental health problems that significantly impact public health. The specific aims of the
      proposed study will address this research gap by conducting a 16-week randomized controlled
      trial of bupropion vs. placebo to evaluate the safety and efficacy of this low abuse
      potential medication on ADHD, nicotine dependence, and cannabis use disorders (not excluding
      other SUD) in 130 adolescents (13-19) receiving concurrent outpatient substance treatment
      (CBT). The study design and analytic approach will enable assessment of the complex
      inter-relationship between change in ADHD, depression/dysphoria (and other psychiatric
      symptoms) and change in nicotine, cannabis and other substance use within and between
      treatment groups. Thus, the study addresses important research gaps in at least two priority
      areas of the National Institute on Drug Abuse/ National Institutes of Health(NIDA/NIH)
      research agenda: 1) research on effective treatments for adolescents with addiction and
      psychiatric comorbidity, and 2) medications development research for nicotine and cannabis
      use disorders in adolescents.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ADHD Rating Scale (ADHD-RS) Total Score</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>DSM-IV ADHD Rating Scale (ADHD-RS) Total Score (clinician administered/adolescent informant). Total scale range 0-54, higher is greater severity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Number of Days of Cigarette Smoking in Past 28 Days</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>The number of days of cigarette smoking in the past 28 days was ascertained based on adolescent self-report using calendar-based timeline follow back procedures. Mean number of days of past 28-day cigarette smoking at baseline was compared to mean number of days of past 28-day cigarette smoking at end of 16-week trial.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Number of Days of Cannabis Use in Past 28 Days</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>The number of days of cannabis use in the past 28 days was ascertained based on adolescent self-report using calendar-based timeline follow back procedures. Mean number of days of past 28-day cannabis use at baseline was compared to mean number of days of past 28-day cannabis use at end of 16-week trial.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <condition>Nicotine Dependence</condition>
  <condition>Cannabis Use Disorder</condition>
  <arm_group>
    <arm_group_label>Bupropion + cognitive behavioral therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adolescents with ADHD, nicotine dependence, and cannabis use disorders receive bupropion + CBT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + cognitive behavioral therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Adolescents with ADHD, nicotine dependence, and cannabis use disorders receive placebo + CBT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion</intervention_name>
    <description>Bupropion (target dose 300 mg/day) + cognitive behavioral therapy; matched placebo + cognitive behavioral therapy</description>
    <arm_group_label>Bupropion + cognitive behavioral therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo + cognitive behavioral therapy</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between the ages of 13 and 19, with a parent or legal guardian available to complete
             parental assessments for minors;

          -  Meet DSM-IV diagnostic criteria for ADHD on the K-SADS-PL;

          -  Schedule for Affective Disorders and Schizophrenia score â‰¥ 22 on the DSM-IV ADHD
             symptom checklist;

          -  Meet DSM-IV criteria for nicotine dependence (and/or cut off score of &gt;3 on modified
             Fagerstrom);

          -  Meet DSM-IV criteria for cannabis abuse or dependence on the Kiddie-Sads-Present and
             Lifetime (K-SADS-PL);

          -  Have used marijuana at least 5 of the past 30 days;

          -  Have used nicotine at least 15 days out of the past 30 days;

          -  Be medically healthy;

          -  If female, subjects must use an effective birth control method if sexually active.

        Exclusion Criteria:

          -  Current or past psychosis;

          -  Bipolar I or II disorder;

          -  A first-degree relative with bipolar I disorder;

          -  A lifetime history of seizure disorder;

          -  Any other chronic or serious medical illnesses;

          -  A lifetime history of eating disorder;

          -  Current pregnancy;

          -  Previous clinically significant adverse reaction to bupropion;

          -  The need to take other psychotropic medications at the time of study entry. Patients
             may have had previous psychotherapy or pharmacotherapy for ADHD or other co-morbidity
             but cannot have been on psychotropic medication for at least one month prior to study
             entry;

          -  Active participation in substance abuse treatment or mental health treatment
             (including outpatient, day-treatment, residential, or inpatient) within 28 days prior
             to signing consent;

          -  Non-English speaking (due to the difficulty in translating the additional materials
             given to the subjects);

          -  Cognitively impaired or of low intelligence;

          -  Breastfeeding;

          -  Current use of other psychotropic medications including nicotine replacement therapy;

          -  Current opiate dependence.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paula D Riggs, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Denver, Adolescent Clinical Research</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>July 8, 2009</study_first_submitted>
  <study_first_submitted_qc>July 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2009</study_first_posted>
  <results_first_submitted>December 23, 2015</results_first_submitted>
  <results_first_submitted_qc>November 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 3, 2019</results_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adolescents</keyword>
  <keyword>Substance Use Disorder</keyword>
  <keyword>Attention Deficit Hyperactivity Disorder</keyword>
  <keyword>Cognitive Behavioral Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
    <mesh_term>Tobacco Use Disorder</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bupropion + Cognitive Behavioral Therapy</title>
          <description>Adolescents with ADHD, nicotine dependence, and cannabis use disorders receive bupropion + CBT.</description>
        </group>
        <group group_id="P2">
          <title>Placebo + Cognitive Behavioral Therapy</title>
          <description>Adolescents with ADHD, nicotine dependence, and cannabis use disorders receive placebo + CBT.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bupropion + Cognitive Behavioral Therapy</title>
          <description>Adolescents with ADHD, nicotine dependence, and cannabis use disorders receive bupropion + CBT.</description>
        </group>
        <group group_id="B2">
          <title>Placebo + Cognitive Behavioral Therapy</title>
          <description>Adolescents with ADHD, nicotine dependence, and cannabis use disorders receive placebo + CBT.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
            <count group_id="B2" value="52"/>
            <count group_id="B3" value="105"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.8" spread="1.5"/>
                    <measurement group_id="B2" value="17.8" spread="1.6"/>
                    <measurement group_id="B3" value="17.8" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in ADHD Rating Scale (ADHD-RS) Total Score</title>
        <description>DSM-IV ADHD Rating Scale (ADHD-RS) Total Score (clinician administered/adolescent informant). Total scale range 0-54, higher is greater severity.</description>
        <time_frame>Baseline, 16 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupropion + Cognitive Behavioral Therapy</title>
            <description>Adolescents with ADHD, nicotine dependence, and cannabis use disorders receive bupropion + CBT.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Cognitive Behavioral Therapy</title>
            <description>Adolescents with ADHD, nicotine dependence, and cannabis use disorders receive placebo + CBT.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in ADHD Rating Scale (ADHD-RS) Total Score</title>
          <description>DSM-IV ADHD Rating Scale (ADHD-RS) Total Score (clinician administered/adolescent informant). Total scale range 0-54, higher is greater severity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.2" lower_limit="-17.1" upper_limit="-11.4"/>
                    <measurement group_id="O2" value="-13.8" lower_limit="-16.6" upper_limit="-11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Number of Days of Cigarette Smoking in Past 28 Days</title>
        <description>The number of days of cigarette smoking in the past 28 days was ascertained based on adolescent self-report using calendar-based timeline follow back procedures. Mean number of days of past 28-day cigarette smoking at baseline was compared to mean number of days of past 28-day cigarette smoking at end of 16-week trial.</description>
        <time_frame>Baseline, 16 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupropion + Cognitive Behavioral Therapy</title>
            <description>Adolescents with ADHD, nicotine dependence, and cannabis use disorders receive bupropion + CBT.
Bupropion: Bupropion (target dose 300 mg/day) + cognitive behavioral therapy; matched placebo + cognitive behavioral therapy</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Cognitive Behavioral Therapy</title>
            <description>Adolescents with ADHD, nicotine dependence, and cannabis use disorders receive placebo + CBT.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of Days of Cigarette Smoking in Past 28 Days</title>
          <description>The number of days of cigarette smoking in the past 28 days was ascertained based on adolescent self-report using calendar-based timeline follow back procedures. Mean number of days of past 28-day cigarette smoking at baseline was compared to mean number of days of past 28-day cigarette smoking at end of 16-week trial.</description>
          <units>days of use</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.1" lower_limit="-6.7" upper_limit="-1.5"/>
                    <measurement group_id="O2" value="-2.7" lower_limit="-5.3" upper_limit="-0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Number of Days of Cannabis Use in Past 28 Days</title>
        <description>The number of days of cannabis use in the past 28 days was ascertained based on adolescent self-report using calendar-based timeline follow back procedures. Mean number of days of past 28-day cannabis use at baseline was compared to mean number of days of past 28-day cannabis use at end of 16-week trial.</description>
        <time_frame>Baseline, 16 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupropion + Cognitive Behavioral Therapy</title>
            <description>Adolescents with ADHD, nicotine dependence, and cannabis use disorders receive bupropion + CBT.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Cognitive Behavioral Therapy</title>
            <description>Adolescents with ADHD, nicotine dependence, and cannabis use disorders receive placebo + CBT.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of Days of Cannabis Use in Past 28 Days</title>
          <description>The number of days of cannabis use in the past 28 days was ascertained based on adolescent self-report using calendar-based timeline follow back procedures. Mean number of days of past 28-day cannabis use at baseline was compared to mean number of days of past 28-day cannabis use at end of 16-week trial.</description>
          <units>days of use</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.7" lower_limit="-7.6" upper_limit="-1.8"/>
                    <measurement group_id="O2" value="-6.5" lower_limit="-9.4" upper_limit="-3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Bupropion + Cognitive Behavioral Therapy</title>
          <description>Adolescents with ADHD, nicotine dependence, and cannabis use disorders receive bupropion + CBT.</description>
        </group>
        <group group_id="E2">
          <title>Placebo + Cognitive Behavioral Therapy</title>
          <description>Adolescents with ADHD, nicotine dependence, and cannabis use disorders receive placebo + CBT.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tonsilitis</sub_title>
                <description>Participant hospitalized overnight for tonsillitis.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head injury</sub_title>
                <description>Participant hospitalized for possible head injury due to a fight.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mania</sub_title>
                <description>Participant hospitalized for alleged bipolar (mania) episode.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Participant hospitalized for two days for pneumonia.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Stomache ache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vomited</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Elevated blood pressure</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Elevated pulse</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Low blood pressure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Low pulse</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Worse headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle pain/soreness</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anger</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Actual study enrollment N=105 was less than targeted enrollment N=130. Thus, negative results should be interpreted with caution because the study was likely underpowered.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Paula Riggs, MD</name_or_title>
      <organization>University of Colorado Denver</organization>
      <phone>303.724.2235</phone>
      <email>paula.riggs@ucdenver.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

